Matching-Adjusted Indirect Comparison of Tarlatamab for Patients with Platinum-Refractory or Platinum-Resistant Extensive-Stage Small-Cell Lung Cancer.
- DOI
- 10.1007/s12325-026-03659-4
- Published
- 2026 Sep
- Container
- Advances in therapy
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s12325-026-03659-4,
title = {Matching-Adjusted Indirect Comparison of Tarlatamab for Patients with Platinum-Refractory or Platinum-Resistant Extensive-Stage Small-Cell Lung Cancer.},
author = {Dirnberger F and Patel S and Boyne DJ and Lan Z and Uyei J and Wang J and Cho S and DeCosta L and Bridges IM and Tapan U},
year = {2026},
journal = {Advances in therapy},
doi = {10.1007/s12325-026-03659-4},
url = {https://doi.org/10.1007/s12325-026-03659-4}
}RIS
TY - JOUR TI - Matching-Adjusted Indirect Comparison of Tarlatamab for Patients with Platinum-Refractory or Platinum-Resistant Extensive-Stage Small-Cell Lung Cancer. AU - Dirnberger F AU - Patel S AU - Boyne DJ AU - Lan Z AU - Uyei J AU - Wang J AU - Cho S AU - DeCosta L AU - Bridges IM AU - Tapan U PY - 2026 JO - Advances in therapy DO - 10.1007/s12325-026-03659-4 UR - https://doi.org/10.1007/s12325-026-03659-4 ER -
APA
F, D., S, P., DJ, B., Z, L., J, U., J, W., S, C., L, D., IM, B., & U, T. (2026). Matching-Adjusted Indirect Comparison of Tarlatamab for Patients with Platinum-Refractory or Platinum-Resistant Extensive-Stage Small-Cell Lung Cancer.. Advances in therapy. https://doi.org/10.1007/s12325-026-03659-4
Source records
- pubmed · retrieved 2026-09-25T21:59:11.130Z
- europe-pmc · retrieved 2026-09-25T21:59:11.144Z